-
Anke Biological Growth Hormone Approved for New Indication for Treatment of Idiopathic Short Stature
Time of Update: 2021-10-01
Text|Pharmaceutical Mission HillsOn September 13, China's National Food and Drug Administration (NMPA) announced that Anke Biotech's newly-declared application for the marketing authorization of recombinant human growth hormone for injection for the treatment of idiopathic short stature (ISS) indications has been officially approved .
-
The drop was as high as 99.1%!
Time of Update: 2021-10-01
" According to the review of the publicity documents, 64 pharmaceutical companies voluntarily applied for price reductions this time, involving 110 drugs, including bevacizumab injection, human interferon α1b for injection, and recombinant human Erythropoietin injection (CHO cells), Aesculus esculentus dispersible tablets, Gastrodin injection, Asarone injection, Cinacalcet hydrochloride tablets, Dexmedetomidine hydrochloride injection, Levofloxacin tablets, Chuangzhi capsules, compound DDB sheet, compound liquorice tablets and the like .
-
After the announcement of the results of the collection of artificial joints, the stock prices of many machinery companies fluctuated
Time of Update: 2021-10-01
Specifically, 44 of the 48 companies that participated in the centralized procurement quotation were selected, and more than 140 products received the "entry ticket" for the centralized procurement, including import manufacturers Johnson & Johnson, Xerox Hui, Shi Sai g, as well as leading domestic Weigao orthopedic, Icahn medical, Chun-li and medical .
-
Why is there a wave of mergers and acquisitions in the medical device industry in 2021?
Time of Update: 2021-10-01
However, in recent years, as competition in the medical device industry has intensified, the volume procurement policy under medical insurance control fees has put pressure on mature businesses for growth; coupled with the acceleration of product iteration in the medical device field, various factors have brought huge challenges to medical device companies.
-
In 2021 ESMO domestic pharmaceutical companies were selected for oral reports with more than ten Cinda and 2 cornerstones each
Time of Update: 2021-10-01
The 2021 European Society of Medical Oncology (ESMO) annual meeting officially opened on September 16, local time . The current annual meeting will last six days and will be held online . The resu
-
Focusing on the future plans of the pharmaceutical equipment giants, the field of biomedicine will become a "sweet potato"?
Time of Update: 2021-10-01
It is foreseeable that in the process of increasing investment in the industry, upstream biopharmaceutical-related equipment will also usher in a new round of opportunities, and demand will continue to grow.
-
Traditional Chinese medicine cross-border "breaking the circle" out of the sense of youthful fashion
Time of Update: 2021-10-01
At the same time, it promotes cross-border cooperation between its pharmaceutical companies and other industries to form a consumer fashion Traditional Chinese medicine has become "trend", such as co-launching health-preserving oatmeal with Quaker, a subsidiary of Pepsi,; Wanglaoji, a subsidiary of PepsiCo, has innovated and changed, and has successively launched new herbal tea products to meet consumers' personalized and diversified health needs.
-
The high-quality development of the biopharmaceutical industry requires continued assistance from pharmaceutical companies
Time of Update: 2021-10-01
In June this year, Henan Province also issued the "Measures to Promote the High-Quality Development of the Biomedical Industry in Our Province" to help serve biomedicine in many aspects such as optimizing the review mechanism, supporting the development of the pharmaceutical industry park, and improving the review and inspection.
-
A chain pharmacy in Changchun, Jilin was fined 220,000 yuan for purchasing drugs illegally
Time of Update: 2021-10-01
A pharmacy in Changchun, Jilin Province purchased drugs illegally and was fined 220,000 yuan .
According to the information in the administrative penalty decision, on April 22, 2021, the Jilin Provincial Drug Administration received a clue that the e-commerce department of Changchun Tianyi Pharmacy Chain Co.
-
Livzon Pharmaceutical's application for drug registration of triptorelin acetate microspheres for injection has been accepted
Time of Update: 2021-10-01
The company's application for triptorelin acetate microspheres for injection The registration and marketing authorization of domestically produced drugs was accepted by the China Food and Drug Administration .
The company is the first domestic enterprise to complete the clinical trials of triptorelin long-acting sustained-release preparations and apply for marketing authorization .
-
20 billion USD BTK inhibitor competition is intensifying. Who is the real "king"?
Time of Update: 2021-10-01
Figure: Zebutinib and Ibrutinib in the treatment of WM head-to-head trialData source: BeiGeneOn December 28, 2020, Baiyueze's two conditional approved indications for MCL and CLL/SLL were included in the National Medical Insurance Catalog, which will take effect on March 1, 2021 .
-
The development of the TCM industry continues to improve, and the TCM equipment industry will also usher in opportunities
Time of Update: 2021-10-01
Industry analysts believe that benefiting from favorable policies, the continued development of the traditional Chinese medicine market, and the increasing demand for patients, although the overall size of the Chinese medical device market in my country was not large in the past, the scale of this market in my country has begun to show up.
-
Haichuang Pharmaceutical's CD44v6 inhibitor for gastrointestinal tumors is accepted for clinical application in China
Time of Update: 2021-10-01
Text|Pharmaceutical Mission HillsRecently, Haichuang Pharmaceuticals announced that the company has introduced a potential "first-in-class" new drug under development from Germany's amcure GmbH, the clinical trial application of HP558 injection has been formally approved by the National Food and Drug Administration (NMPA) of China Accept .
-
Under the multiple pressures of centralized procurement and foreign investment, where is the way out for local pharmaceutical companies?
Time of Update: 2021-10-01
On the one hand, under the background of normalization of centralized procurement, drug price reduction has become a trend, the industry is facing innovation and transformation, a group of small and medium-sized enterprises will face the situation of elimination, and the overall market competition will become more fierce; on the other hand, since China joined ICH in 2017, Mutual recognition of data has enabled local pharmaceutical companies to enjoy ICH dividends.
-
BeiGene announced to be included in the FTSE Russell Index
Time of Update: 2021-10-01
Cambridge, MA, USA and Beijing, China, September 20, 2021/PRNewswire/ - BeiGene (NASDAQ: BGNE; HKEX: 06160) is a science-based global biotechnology company focused on development, innovation, and affordable The drug is designed to improve the effectiveness of treatment and increase the accessibility of drugs for patients around the world .
-
With one shot, the cancer cells disappear!
Time of Update: 2021-10-01
According to the industry, although CAR-T drugs are expensive, such as a single dose of Akirensai injection reaching 1.
In addition, it’s worth noting that WuXi Junuo issued an announcement on September 3 that its CAR-T product targeting CD19, Ruiji Oransay injection, was approved for marketing .
-
The domestic rare disease industry has huge development potential, and the market may exceed 60 billion yuan in 2030
Time of Update: 2021-10-01
The industry predicts that according to the current industry development trend, as domestic pharmaceutical companies continue to make efforts in the rare disease drug market in the future, the market potential will continue to grow substantially .
-
Zidoramivudine Tablets, a subsidiary of Northeast Pharmaceuticals, obtained a drug registration certificate
Time of Update: 2021-10-01
On September 14, Northeast Pharmaceutical issued an announcement stating that its wholly-owned subsidiary, First Pharmaceutical Zidoramidivudine Tablets, had recently received the "Drug Registration C
-
To Biao Yangzijiang and Hengrui!
Time of Update: 2021-10-01
There are 16 manufacturers of dexmedetomidine hydrochloride injection, of which 14 companies have been reviewed by Yangtze River Pharmaceutical Group, Jiangsu Hengrui Pharmaceutical, Nanjing Zhengda Tianqing Pharmaceutical, and Hunan Kelun Pharmaceutical; dexmedetomidine hydrochloride There are only two manufacturers of sodium chloride injection, Jiangsu Hengrui Pharmaceutical and Chengdu Better Pharmaceutical, both of which have been approved for imitation of category 3 and are deemed to have been reviewed .
-
my country's pharmaceutical manufacturing industry is ushering in a "golden development period", and the pharmaceutical machinery industry will also benefit
Time of Update: 2021-10-01
It should be noted that despite policy support, increased investment, and the continued improvement of the pharmaceutical environment, the pharmaceutical equipment industry will usher in opportunities .
